Role of anti-inflammatory adipokines in obesity-related diseases

Trends in Endocrinology and Metabolism

Volumn 25, Issue 7, 2014, Pages 348-355

  Ohashi, Koji ^a   Shibata, Rei ^a   Murohara, Toyoaki ^a   Ouchi, Noriyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipolin; Adiponectin; CTRP3; CTRP9; Omentin 1

Indexed keywords

ADIPOCYTOKINE; ADIPOLIN; ADIPONECTIN; COMPLEMENT COMPONENT C1Q; CTRP12 PROTEIN; CTRP3 PROTEIN; CTRP6 PROTEIN; CTRP9 PROTEIN; OMENTIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; C1QTNF3 PROTEIN, HUMAN; CYTOKINE; FAM132A PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; HUMAN; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; ANIMAL; COMPLICATION; IMMUNOLOGY; METABOLISM;

ADIPOKINES; ADIPONECTIN; ANIMALS; CYTOKINES; GPI-LINKED PROTEINS; HUMANS; LECTINS; OBESITY; TUMOR NECROSIS FACTORS;

EID: 84903474732     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.03.009     Document Type: Review

References (76)

1. Friedman J.M. A war on obesity, not the obese. Science 2003, 299:856-858.
2. Matsuzawa Y., et al. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J. Atheroscler. Thromb. 2011, 18:629-639.
3. Ouchi N., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
4. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
5. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
6. Ouchi N., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
7. Ouchi N., et al. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 2003, 14:561-566.
8. Ouchi N., et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010, 329:454-457.
9. Enomoto T., et al. Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolism. J. Biol. Chem. 2011, 286:34552-34558.
10. Maeda K., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 1996, 221:286-289.
11. Arita Y., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
12. Ryo M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004, 68:975-981.
13. Hotta K., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126-1133.
14. Iwashima Y., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
15. Kumada M., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003, 23:85-89.
16. Ouchi N., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
17. Esposito K., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J. Am. Med. Assoc. 2003, 289:1799-1804.
18. Yokota T., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
19. Yamaguchi N., et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005, 579:6821-6826.
20. Ouchi N., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
21. Okamoto Y., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
22. Okamoto Y., et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ. Res. 2008, 102:218-225.
23. Komura N., et al. Adiponectin protein exists in aortic endothelial cells. PLoS ONE 2013, 8:e71271.
24. Summer R., et al. Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L1035-L1042.
25. Konter J.M., et al. Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J. Immunol. 2012, 188:854-863.
26. Shibata R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
27. Holland W.L., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 2011, 17:55-63.
28. Wang Y., et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009, 119:835-844.
29. Kondo K., et al. Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ. Cardiovasc. Interv. 2010, 3:166-173.
30. Okada-Iwabu M., et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503:493-499.
31. Ohashi K., et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem. 2010, 285:6153-6160.
32. Xu H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
33. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
34. Lovren F., et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H656-H663.
35. Mandal P., et al. Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J. Biol. Chem. 2011, 286:13460-13469.
36. Takemura Y., et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest. 2007, 117:375-386.
37. Wong G.W., et al. A family of Acrp30/adiponectin structural and functional paralogs. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10302-10307.
38. Wong G.W., et al. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem. J. 2008, 416:161-177.
39. Wong G.W., et al. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 2009, 23:241-258.
40. Kambara T., et al. CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism. J. Biol. Chem. 2012, 287:18965-18973.
41. Maeda T., et al. Molecular cloning and characterization of a novel gene, CORS26, encoding a putative secretory protein and its possible involvement in skeletal development. J. Biol. Chem. 2001, 276:3628-3634.
42. Peterson J.M., et al. C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J. Biol. Chem. 2010, 285:39691-39701.
43. Hofmann C., et al. C1q/TNF-related protein-3 (CTRP-3) is secreted by visceral adipose tissue and exerts antiinflammatory and antifibrotic effects in primary human colonic fibroblasts. Inflamm. Bowel Dis. 2011, 17:2462-2471.
44. Kopp A., et al. C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology 2010, 151:5267-5278.
45. Weigert J., et al. The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett. 2005, 579:5565-5570.
46. Wolfing B., et al. Effects of the new C1q/TNF-related protein (CTRP-3) 'cartonectin' on the adipocytic secretion of adipokines. Obesity (Silver Spring) 2008, 16:1481-1486.
47. Yi W., et al. C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation 2012, 125:3159-3169.
48. Kim M.J., et al. C1qTNF-related protein-6 increases the expression of interleukin-10 in macrophages. Mol. Cells 2010, 30:59-64.
49. Lee W., et al. C1qTNF-related protein-6 mediates fatty acid oxidation via the activation of the AMP-activated protein kinase. FEBS Lett. 2010, 584:968-972.
50. Zheng Q., et al. C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2616-2623.
51. Peterson J.M., et al. CTRP9 transgenic mice are protected from diet-induced obesity and metabolic dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305:R522-R533.
52. Uemura Y., et al. Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and neointimal formation. FASEB J. 2012, 27:25-33.
53. Su H., et al. Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFalpha-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice. Basic Res. Cardiol. 2013, 108:315.
54. Sun Y., et al. C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 2013, 128:S113-S120.
55. Wei Z., et al. C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. J. Biol. Chem. 2012, 287:10301-10315.
56. Tan B.K., et al. Metformin increases the novel adipokine adipolin/CTRP12: role of the AMPK pathway. J. Endocrinol. 2013, 219:101-108.
57. Wei Z., et al. Endopeptidase cleavage generates a functionally distinct isoform of C1q/tumor necrosis factor-related protein-12 (CTRP12) with an altered oligomeric state and signaling specificity. J. Biol. Chem. 2012, 287:35804-35814.
58. Enomoto T., et al. Regulation of adipolin/CTRP12 cleavage by obesity. Biochem. Biophys. Res. Commun. 2012, 428:155-159.
59. Bell-Anderson K.S., et al. Loss of Kruppel-like factor 3 (KLF3/BKLF) leads to upregulation of the insulin-sensitizing factor adipolin (FAM132A/CTRP12/C1qdc2). Diabetes 2013, 62:2728-2737.
60. Enomoto T., et al. Transcriptional regulation of an insulin-sensitizing adipokine adipolin/CTRP12 in adipocytes by Kruppel-like factor 15. PLoS ONE 2013, 8:e83183.
61. Tsuji S., et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J. Biol. Chem. 2001, 276:23456-23463.
62. Yang R.Z., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1253-E1261.
63. de Souza Batista C.M., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
64. Moreno-Navarrete J.M., et al. Circulating omentin concentration increases after weight loss. Nutr. Metab. (Lond.) 2010, 7:27.
65. Tan B.K., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
66. Mahde A., et al. Study of omentin1 and other adipokines and hormones in PCOS patients. Oman Med. J. 2009, 24:108-118.
67. Shibata R., et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol. Metab. Syndr. 2012, 4:37.
68. Shibata R., et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens. Res. 2011, 34:1309-1312.
69. Yoo H.J., et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc. Diabetol. 2011, 10:103.
70. Shibata R., et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219:811-814.
71. Shang F.J., et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011, 16:657-662.
72. Yamawaki H., et al. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem. Biophys. Res. Commun. 2010, 393:668-672.
73. Maruyama S., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J. Biol. Chem. 2012, 287:408-417.
74. Yamawaki H., et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem. Biophys. Res. Commun. 2011, 408:339-343.
75. Zhong X., et al. Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochem. Biophys. Res. Commun. 2012, 425:401-406.
76. Kazama K., et al. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur. J. Pharmacol. 2012, 686:116-123.